DXN Holdings (5318) Fair Value & Analysis
Consumer Defensive · MY · Market cap 2.2B MYR
Analysis
DXN Holdings (5318) currently trades at 0.4650 MYR, while our model-based Fair Value estimate is 1.15 MYR — implying the stock looks roughly 147.3% undervalued today. We read business quality at 92/100 (high quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
DXN Holdings Bhd. manufactures and sales health supplements and other products on direct sales basis in Latin America, Malaysia, Asia, North America, Africa, Europe, the Middle East, and Oceania. It offers coffee, tea, nutritious drinks, juices, confectionery and biscuits, herbs, mushrooms and fungi, premixes, toothpastes, face masks, perfumes, body foams, shampoos, soaps, powders, travel kits, toothbrushes, sanitizers, massage and baby oil, lipsticks, finish powders, and scrubs. The company also operates cafes, glamping resort, tourism village complex, marine sanctuary, tour activities, and hold properties. In addition, it provides health food, non-alcoholic drinks, traditional medicines, biodiesel, and spirulina and cordyceps cereals, as well as other food products. Further, it offers information technology advising and consulting services; trades in computer hardware and software equipment; and plantation and cultivation of rubber trees and cash crops. Additionally, it engages in…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.